Plain-English translation of NCT07155317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether the time of day you receive immunotherapy drugs— and —affects how well they work against advanced melanoma. Some research suggests that our bodies' internal clocks may influence how well cancer treatments work, so this study will compare giving this medication in the morning versus midday to see if timing matters.
Advanced melanoma is a serious form of skin cancer, and while immunotherapy has helped many patients, doctors want to find ways to make it work even better. This medication helps your immune system fight cancer, but researchers suspect that giving it at different times of day might improve how effective it is and reduce side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive the medication either in the morning (8 a.m.–11 a.m.) or midday (11 a.m.–2 p.m.). You will receive infusions every 3 weeks for 4 cycles, then continue with maintenance treatment for up to 2 years. Throughout the study, you'll wear a small device that tracks your sleep and activity patterns, have blood tests and imaging scans (CT or MRI), and may have optional tissue samples taken. Visits will include monitoring for side effects and checking how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States